Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors

Progress in Cardiovascular Diseases
Spyros KokolisJonathan D Marmur

Abstract

Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.

References

Feb 28, 1979·Biochemical and Biophysical Research Communications·R D RosenbergL H Lam
Dec 1, 1992·The Annals of Pharmacotherapy·K A Stringer, J Lindenfeld
Jul 1, 1990·Baillière's Clinical Haematology·F A Ofosu, T W Barrowcliffe
Jan 1, 1991·Haemostasis·J W FentonJ M Maraganore
Aug 12, 1986·Biochemistry·S R Stone, J Hofsteenge
Mar 15, 1981·Thrombosis Research·W Anderson, J E Harthill
Oct 16, 1980·Biochemical and Biophysical Research Communications·R D RosenbergW T Gardner
Dec 1, 1993·Australian and New Zealand Journal of Medicine·H White
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Jan 1, 1996·Seminars in Thrombosis and Hemostasis·A Tulinsky
Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators
Jun 1, 1997·Thrombosis Research·B PötzschG Müller-Berghaus
Sep 4, 1997·The New England Journal of Medicine·J I Weitz
Jan 1, 1997·Seminars in Thrombosis and Hemostasis·M J HurstingR P Schwarz
Jan 6, 2001·Lancet·UNKNOWN ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Mar 7, 2001·American Heart Journal·D J KereiakesT M Shimshak
Mar 14, 2001·Circulation·A Greinacher, N Lubenow
Sep 29, 2001·International Journal of Cardiology·J P ColletA Ankri
Dec 1, 2001·Journal of Thrombosis and Thrombolysis·M MoledinaP J Gandhi
Feb 7, 2002·Lancet·UNKNOWN Direct Thrombin Inhibitor Trialists' Collaborative Group
Feb 14, 2002·British Journal of Haematology·Mark A CrowtherAnthony K C Chan
Jun 8, 2002·Current Cardiology Reports·Heidar ArjomandMarc Cohen
Jun 18, 2002·Pharmacotherapy·Michael D Reed, Dawn Bell
Jun 28, 2002·Clinical Pharmacology and Therapeutics·Richard RobsonChristopher Frampton

❮ Previous
Next ❯

Citations

Sep 23, 2009·American Journal of Therapeutics·Param Puneet SinghSandeep Khosla
Mar 9, 2005·Endocrinology and Metabolism Clinics of North America·John B Buse, Julio Rosenstock
Sep 8, 2005·The Annals of Pharmacotherapy·A Scott Mathis, James J Gugger
Apr 4, 2017·Biomolecules & Therapeutics·Joo Hee KimHye Sun Gwak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.